Sanofi Says Its $2.5 Billion Biotech Takeover Is Just the Beginning
Sanofi has the perfect gift for investors: Investment in its most promising businesses with plans to keep growing the dividend.
Synthorx(THOR)
NASDAQ
THOR
Synthorx INC
Interactive Chart
News & Analysis: Synthorx
Sanofi Is Paying a 172% Premium to Buy Synthorx -- and It Sounds Like a Good Deal for Both
Sanofi, with sales falling in its older businesses, boosts its higher-growth immuno-oncology business with the $2.5 billion purchase of Synthorx.
What Happened in the Stock Market Today
Two big deals for cancer drug companies made news today. Merck plans to buy ArQule and Sanofi will pay up to buy Synthorx.
Why Synthorx Stock Is Soaring Today
Sanofi and the clinical-stage biotech Synthorx announced a $2.5 billion buyout agreement Monday morning.
3 Top Stocks That Aren't on Wall Street's Radar
Three companies in industries that Wall Street isn't paying enough attention to. Don't miss out, too.
